Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000950170-25-073071
Filing Date
2025-05-15
Accepted
2025-05-15 21:13:43
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 9505
2 EX-99.A ck0001669811-ex99_a.pdf EX-99.A 61998
  Complete submission text file 0000950170-25-073071.txt   96747
Mailing Address 10531 4S COMMONS DRIVE SUITE 166-550 SAN DIEGO CA 92127
Business Address 1035 CAMBRIDGE STREET SUITE 18A CAMBRIDGE MA 02141 (617) 798-6700
Ernexa Therapeutics Inc. (Subject) CIK: 0000748592 (see all company filings)

EIN.: 311103425 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-42217 | Film No.: 25956750
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address
Business Address
HALPERN JOHN D (Filed by) CIK: 0001234950 (see all company filings)

Type: SCHEDULE 13G/A